Between January and August 2018, Russia produced 212.8 bln RUB worth of pharmaceutical drugs (dispatch prices, VAT included), which is in monetary terms only 0.1% higher than that of the same period of 2017. In physical terms, Russia produced 2.61 bln units. The dynamics are -10.4%, which have been gradually decreasing for 10 months.

August brings the lowest production volume in physical terms (0.27 bln unit), as well as the lowest long-term dynamics (-24%) in 2018. The growing number of minimum dosage units (MDU) compensates for the actual consumption volume of Russian pharmaceuticals. If calculated in MDU, the dynamics are -4.5%, which is significantly better than those in physical terms.

The dynamics of both OTC and Rx drug production in physical terms are -10.4%. If calculated in MDU, the dynamics of OTC drug production are -9.4%, while those of Rx drug production are +1.3%. Tatkhimpreparaty and Obnovleniye are the companies with the lowest dynamics of OTC drug production, with -27%. However, there are also companies with positive dynamics. Uralbiofarm has the highest dynamics (+14%), its Citramon accounts for more than 37% of the total production, while Calcium Gluconate has the biggest dynamics (a nearly 6 times increase).

Syntez and Ozon have the worst dynamics among the producers of Rx drugs, with -28% and -23%, respectively. Vertex has the highest dynamics (+30%), in particular due to a 6 times increase of Elzhina.

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2017 – August 2018